Compare MCB & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | WVE |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2015 |
| Metric | MCB | WVE |
|---|---|---|
| Price | $98.48 | $5.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $98.67 | $29.81 |
| AVG Volume (30 Days) | 137.7K | ★ 3.1M |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 2.92 | N/A |
| Revenue | ★ $11,053,000.00 | $3,704,000.00 |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | $85.67 |
| P/E Ratio | $34.60 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $64.66 | $5.02 |
| 52 Week High | $102.04 | $21.73 |
| Indicator | MCB | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 44.59 |
| Support Level | $86.38 | $5.48 |
| Resistance Level | $102.04 | $6.48 |
| Average True Range (ATR) | 2.49 | 0.32 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 49.34 | 34.54 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.